Clinical trial · Interventional
Clinical Utility of MyProstateScore 2.0 P2
An Extension Study of LynxDx's Ongoing Determination of Clinical Utility of MyProstateScore 2.0 Test: A Combined CPV-Based, Patient-Level Assessment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The decision to stop the study was made by the sponsor, based solely on timeline constraints.
Summary
Brief summary (as posted)
This is an extension of an ongoing study. Preliminary results from the ongoing study indicate that the MyProstateScore 2.0 (MPS 2.0) Test is significantly improving early diagnosis of prostate cancer. This extension will allow us to ask the study participants in the ongoing study to share patient-level data for chart abstraction. The specific purpose of this study is to generate high-quality real-world data on the clinical utility of LynxDx's new MPS 2.0 test.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MyProstateScore 2.0 Results | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control arm - Baseline comparison
- description
- The Control group treats their simulated patients using standard practice and has no introduction to the new MyProststate 2.0 test.
- type
- EXPERIMENTAL
- label
- MyProstateScore 2.0
- description
- The intervention will receive information regarding the MyProstateScore 2.0 test and will be given the test results in their round of CPV information and for each sample that they submit.
- interventionNames
- Other: MyProstateScore 2.0 Results
Primary outcomes (6)
- measure
- Baseline levels of variation in the assessment, surveillance, and management of patients at high risk for prostate cancer among all study participants.
- timeFrame
- [9 months]
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Licensed urologist * Have practiced as a urologist for greater than 2 but less than 40 years * Commonly treats patients at risk for prostate cancer * Practicing in the United States * English-speaking * Access to the internet * Informed and voluntarily consented to be in the study Exclusion Criteria: * Non-English speaking * Not a licensed primary care provider * Unable to access the internet * Not practicing in the U.S. * Do not voluntarily consent to be in the study
References
Publications (0)
Data not yet available